doxazosin has been researched along with Urination Disorders in 35 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 9.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia." | 9.15 | Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. ( Jin, J; Wan, B; Wang, X; Yang, Y; Ye, H; Yu, W; Zhang, K; Zhang, N; Zhong, C, 2011) |
| "A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH)." | 9.08 | Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. ( Braun, K; Dias, N; Fawzy, A; Gaffney, M; Ice, K; Lewis, GP, 1995) |
| "Doxazosin, a well established treatment in patients with bothersome lower urinary tract symptoms from benign prostatic hyperplasia (BPH), is available in a new controlled-release formulation, doxazosin gastrointestinal therapeutic system (GITS)." | 8.82 | Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. ( Goldsmith, DR; Plosker, GL, 2005) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 6.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| " However, the incidence of nocturnal enuresis, urgency attacks, and daytime incontinence were significantly reduced compared with baseline in the tizanidine group (P=." | 5.16 | Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. ( Dawaba, M; El-Assmy, MM; El-Hefnawy, AS; Hafez, AT; Helmy, T; Sarhan, O, 2012) |
| "This study sought to investigate the clinical efficacy and safety of combined oral therapy with sildenafil and doxazosin GITS compared to sildenafil monotherapy in treating Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)." | 5.15 | An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. ( Gao, B; Guo, YL; Jin, Z; Liu, JH; Lu, J; Song, WD; Sun, XZ; Tang, YX; Xin, ZC; Zhang, ZC, 2011) |
| "In Chinese patients with LUTS/BPH, doxazosin-GITS is slightly better than tamsulosin in reducing the frequency of nocturia." | 5.15 | Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. ( Jin, J; Wan, B; Wang, X; Yang, Y; Ye, H; Yu, W; Zhang, K; Zhang, N; Zhong, C, 2011) |
| "To compare the efficacy and safety of a combination therapy, doxazosin plus tenoxicam, and doxazosin alone for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), as various combination therapies increase the efficacy of medical therapy." | 5.14 | Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. ( Aslan, G; Bozkurt, O; Demir, O; Esen, AA; Ozdemir, I, 2009) |
| "Compared to placebo, doxazosin did not demonstrate a significant objective benefit, but produced a significant subjective benefit in the treatment of urinary incontinence secondary to voiding dysfunction." | 5.11 | Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. ( Elkins, D; Husmann, DA; Karnes, RJ; Kramer, SA; Rathbun, SR, 2005) |
| "A 16-week, double-blind, placebo controlled, dose titration study was done on 100 normotensive patients age 45 years or older to determine the efficacy and safety of doxazosin, a selective alpha 1-adrenoceptor antagonist, in the treatment of benign prostatic hyperplasia (BPH)." | 5.08 | Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. ( Braun, K; Dias, N; Fawzy, A; Gaffney, M; Ice, K; Lewis, GP, 1995) |
| "Doxazosin, a well established treatment in patients with bothersome lower urinary tract symptoms from benign prostatic hyperplasia (BPH), is available in a new controlled-release formulation, doxazosin gastrointestinal therapeutic system (GITS)." | 4.82 | Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. ( Goldsmith, DR; Plosker, GL, 2005) |
| "We investigate the results of ambulatory urodynamic evaluation of men with lower urinary tract symptoms (LUTS) believed secondary to benign prostatic hyperplasia (BPH) treated with doxazosin and compare these results to conventional urodynamic study." | 3.69 | Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. ( Contreras, BA; Gerber, GS; Rukstalis, DB, 1997) |
| "Doxazosin and alfuzosin were both well tolerated, with most all-cause adverse events reported as mild or moderate." | 2.71 | Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. ( de Reijke, TM; Klarskov, P, 2004) |
| "The role of alpha-blockers for managing bladder outlet obstruction remains relatively unexplored in children." | 2.69 | alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. ( Austin, PF; Cain, MP; Casale, AJ; Homsy, YL; Masel, JL; Rink, RC, 1999) |
| "A total of 248 hypertensive patients 45 years old or older with benign prostatic hyperplasia (BPH) was included in this 16-week, multicenter, double-blind, placebo-controlled, parallel-group dose-response study." | 2.68 | Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. ( Chrysant, SG; Conn, RL; Dias, N; Gaffney, M; Gillenwater, JY; Ice, K; Roy, J, 1995) |
| "Men participating in the 2001 and 2002 Prostate Cancer Awareness Week screening for prostate cancer were given a self-administered questionnaire." | 1.32 | Herbal and vitamin supplement use in a prostate cancer screening population. ( Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (20.00) | 18.2507 |
| 2000's | 23 (65.71) | 29.6817 |
| 2010's | 5 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, KE | 1 |
| Proshchaev, KI | 1 |
| Slivkin, VV | 1 |
| Filippov, SV | 1 |
| Il'nitskiĭ, AN | 1 |
| Gileva, VV | 1 |
| Liutsko, VV | 1 |
| Ozdemir, I | 1 |
| Bozkurt, O | 1 |
| Demir, O | 1 |
| Aslan, G | 1 |
| Esen, AA | 1 |
| Delgado Alvira, R | 1 |
| Calleja Aguayo, E | 1 |
| Rihuete Heras, MA | 1 |
| Ruiz de Temiño Bravo, M | 1 |
| Gracia Romero, J | 1 |
| Molina Vázquez, ME | 1 |
| Somoza Arguibay, I | 1 |
| Palacios, MG | 1 |
| Gómez Veiras, JR | 1 |
| González, M | 1 |
| Tellado, M | 1 |
| Pais, E | 1 |
| Dargallo, T | 1 |
| Vela, D | 1 |
| Jin, Z | 1 |
| Zhang, ZC | 1 |
| Liu, JH | 1 |
| Lu, J | 1 |
| Tang, YX | 1 |
| Sun, XZ | 1 |
| Song, WD | 1 |
| Gao, B | 1 |
| Guo, YL | 1 |
| Xin, ZC | 1 |
| Zhang, K | 1 |
| Yu, W | 1 |
| Jin, J | 1 |
| Ye, H | 1 |
| Wang, X | 1 |
| Zhang, N | 1 |
| Yang, Y | 1 |
| Zhong, C | 1 |
| Wan, B | 1 |
| El-Hefnawy, AS | 1 |
| Helmy, T | 1 |
| El-Assmy, MM | 1 |
| Sarhan, O | 1 |
| Hafez, AT | 1 |
| Dawaba, M | 1 |
| Merrick, GS | 1 |
| Butler, WM | 1 |
| Wallner, KE | 1 |
| Lief, JH | 1 |
| Galbreath, RW | 1 |
| Ukhal', MI | 2 |
| Strashnyĭ, VV | 2 |
| Malomuzh, OI | 2 |
| Shumilin, MV | 2 |
| O'Leary, MP | 1 |
| Yang, SS | 1 |
| Wang, CC | 1 |
| Chen, YT | 1 |
| Barqawi, A | 1 |
| Gamito, E | 1 |
| O'Donnell, C | 1 |
| Crawford, ED | 1 |
| Brown, GA | 1 |
| Sussman, DO | 1 |
| de Reijke, TM | 1 |
| Klarskov, P | 1 |
| Watson, V | 1 |
| Ryan, M | 1 |
| Brown, CT | 1 |
| Barnett, G | 1 |
| Ellis, BW | 1 |
| Emberton, M | 1 |
| Donohoe, JM | 1 |
| Combs, AJ | 1 |
| Glassberg, KI | 1 |
| Bozlu, M | 1 |
| Ulusoy, E | 1 |
| Cayan, S | 1 |
| Akbay, E | 2 |
| Görür, S | 1 |
| Kramer, SA | 1 |
| Rathbun, SR | 1 |
| Elkins, D | 1 |
| Karnes, RJ | 1 |
| Husmann, DA | 1 |
| Slavov, Ch | 1 |
| Dimitrov, R | 1 |
| Yucel, S | 1 |
| Akkaya, E | 1 |
| Guntekin, E | 1 |
| Kukul, E | 1 |
| Akman, S | 1 |
| Melikoglu, M | 1 |
| Baykara, M | 1 |
| Goldsmith, DR | 1 |
| Plosker, GL | 1 |
| Kaplan, SA | 2 |
| McConnell, JD | 1 |
| Roehrborn, CG | 1 |
| Meehan, AG | 1 |
| Lee, MW | 1 |
| Noble, WR | 1 |
| Kusek, JW | 1 |
| Nyberg, LM | 1 |
| Desgrandchamps, F | 1 |
| Kroll, P | 1 |
| Jankowski, A | 1 |
| Maćkowiak, J | 1 |
| Shaplygin, LV | 1 |
| Ullrich, PM | 1 |
| Lutgendorf, SK | 1 |
| Kreder, KJ | 1 |
| Fawzy, A | 1 |
| Braun, K | 1 |
| Lewis, GP | 1 |
| Gaffney, M | 2 |
| Ice, K | 2 |
| Dias, N | 2 |
| Gillenwater, JY | 1 |
| Conn, RL | 1 |
| Chrysant, SG | 1 |
| Roy, J | 1 |
| Meier, AH | 1 |
| van Waalwijk van Doorn, ES | 1 |
| Delaere, KP | 1 |
| Gerber, GS | 2 |
| Contreras, BA | 2 |
| Rukstalis, DB | 1 |
| Turner, CD | 1 |
| Kuznetsov, D | 1 |
| Austin, PF | 1 |
| Homsy, YL | 1 |
| Masel, JL | 1 |
| Cain, MP | 1 |
| Casale, AJ | 1 |
| Rink, RC | 1 |
| Stifelman, M | 1 |
| Avillo, C | 1 |
| Reis, RB | 1 |
| Te, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level[NCT01678313] | Phase 2 | 140 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Multicenter Randomized Open-labelled Trial Which Aims to Show Non-inferiority of Adverse Events Risk During the Maintenance of Oral-anticoagulation in the Surgery of Benign Prostatic Hypertrophy by Laser Photovaporization[NCT03297281] | 389 participants (Anticipated) | Interventional | 2017-10-30 | Recruiting | |||
| CSP #407 - Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer[NCT00007644] | Phase 3 | 731 participants (Actual) | Interventional | 1994-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Efficacy:~Change from Baseline in the International Prostate Symptom Score (IPSS) from baseline and 3 months The International Prostate Symptom Score (IPSS) is an 7 symptom questions including 4 voiding questions (IPSS Voiding), 3 storage questions (IPSS Storage) The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always.~Total IPSS score = IPSS voiding + IPSS Storage Rang = 0 to 35 (asymptomatic to very symptomatic). Mild = 0 to 7; Moderate = 8 to 19; Severe = 20 to 35~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 12.0 | 7.70 | -4.31 |
| Study Group | 13.1 | 6.45 | -6.63 |
"Efficacy:~Change from Baseline in the IPSS Storage from baseline and 3 months The IPSS subscore (IPSS Storage) is a 3 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Storage score can therefore range from 0 to 15 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 6.06 | 4.01 | -2.05 |
| Study Group | 5.59 | 3.09 | -2.5 |
"Efficacy:~Change from Baseline in the IPSS Voiding from baseline and 3 months. The IPSS subscore (IPSS Voiding) questionnaires is a 4 symptom questions. The symptom score have 6-point scale ranging from 0 Not at all to 5 Almost always. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom.~The total IPSS Voiding score can therefore range from 0 to 20 (asymptomatic to very symptomatic).~Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 5.54 | 3.45 | -2.09 |
| Study Group | 7.55 | 3.84 | -3.71 |
"Efficacy:~Change from Baseline in the maximum flow rate (Qmax) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL/s (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 10.0 | 11.9 | 1.9 |
| Study Group | 12.2 | 12.2 | -0.09 |
"Efficacy:~Change from Baseline in the serum PSA level from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 15.2 | 13.5 | -1.70 |
| Study Group | 10.8 | 9.42 | -1.43 |
"Efficacy:~Change from Baseline in the Void Volume (VV) from baseline and 3 months Change = Month 3 minus Baseline value" (NCT01678313)
Timeframe: Baseline and 3 months after initial treatment
| Intervention | mL (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | Change | |
| Control Group | 175 | 231 | 55.7 |
| Study Group | 259 | 227 | -32.3 |
Number of deaths from any cause. (NCT00007644)
Timeframe: From date of randomization until date of death from any cause, assessed until end of study, up to 16 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Radical Prostatectomy | 171 |
| Watchful Waiting | 183 |
2 reviews available for doxazosin and Urination Disorders
| Article | Year |
|---|---|
Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Delayed-Action Preparations; Doxazosin; Human | 2005 |
[The objective of medical treatment: relieve the symptoms or stop the course?].
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; C | 2006 |
14 trials available for doxazosin and Urination Disorders
| Article | Year |
|---|---|
Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Cyclooxygenase 2 Inhibitors; Doxazosin; Drug Therapy, Combination; Hum | 2009 |
An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: Aged; Asian People; China; Doxazosin; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; | 2011 |
Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Nocturi | 2011 |
Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Anorexia; Child; Chil | 2012 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; H | 2002 |
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Doxazosin; Drug Administration Schedule; Humans; | 2004 |
Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Double-Blind Method; Doxazosin; Female; Humans; Mal | 2005 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prosta | 2006 |
[The comparative study on selective alpha1-blocker and behavioural therapy in the treatment of discoordinated voiding in children].
Topics: Adolescent; Adrenergic alpha-Antagonists; Behavior Therapy; Child; Child, Preschool; Doxazosin; Exer | 2006 |
Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study.
Topics: Aged; Blood Pressure; Double-Blind Method; Doxazosin; Follow-Up Studies; Heart Rate; Humans; Male; M | 1995 |
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Heart Rate; | 1995 |
Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Prospec | 1998 |
[The use of the alpha 1-adrenoblocker doxazosin in the pharmacotherapy of disorders of urine outflow of spastic origin].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Delayed-Action Preparations; Doxazosin; Humans; Male; Midd | 1998 |
alpha-Adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; | 1999 |
19 other studies available for doxazosin and Urination Disorders
| Article | Year |
|---|---|
How many drugs for LUTS due to BPH are too many?
Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; E | 2008 |
[Clinical and neuroimmunoendocrine effects of doxasosine in treatment of benign hyperplasia of the prostate in elderly people].
Topics: Adrenergic alpha-Antagonists; Aged; Aging; Cell Adhesion Molecules; Doxazosin; Humans; Interleukin-6 | 2008 |
[Our experience with the use of alpha-lithic therapy in the treatment of voiding dysfunction].
Topics: Adrenergic alpha-1 Receptor Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; Q | 2010 |
[Role of alpha antagonists in uncoordinated micturition syndrome in childhood].
Topics: Adrenergic alpha-1 Receptor Antagonists; Child; Child, Preschool; Doxazosin; Female; Humans; Male; R | 2010 |
[Drug therapy of spastic disorder of urine outflow in patients with spinal injury and spinal cord injury].
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Blood Pressure; Doxazosin; Humans; Middle Aged; Spi | 2002 |
By the way, doctor. I'm 77 and have an enlarged prostate. I take Proscar once a day and saw palmetto three times a day. Yet I still have to get up two to seven times a night to urinate. What can I do to reduce the frequency of urination?
Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finaste | 2003 |
Effectiveness of alpha1-adrenergic blockers in boys with low urinary flow rate and urinary incontinence.
Topics: Adolescent; Adrenergic alpha-Antagonists; Child; Child, Preschool; Doxazosin; Humans; Male; Treatmen | 2003 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietar | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Dr | 2004 |
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Azasteroids; Doxazosin; Dutasteride; H | 2004 |
Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Child; Child, Preschool; Doxazosin; Electromyograph | 2005 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; | 2004 |
[LUTS in women and possible therapeutic effects of alfa1-adrenoblockers].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Female; Humans; Middle Aged; Receptors, Adrene | 2004 |
Can alpha-blocker therapy be an alternative to biofeedback for dysfunctional voiding and urinary retention? A prospective study.
Topics: Adrenergic alpha-Antagonists; Biofeedback, Psychology; Child; Child, Preschool; Doxazosin; Female; H | 2005 |
[Using of alpha1-adrenoreceptor blockers in urologic practice].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Doxazosin; Humans; Midd | 2007 |
Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia.
Topics: Aged; Blood Pressure; Doxazosin; Finasteride; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System | 2007 |
A 3-month double-blind study of doxazosin as treatment for benign prostate bladder outlet obstruction.
Topics: Doxazosin; Humans; Male; Prostatic Diseases; Randomized Controlled Trials as Topic; Urinary Bladder | 1995 |
Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Doxazosin; Humans; Male; Middle Aged; Monitor | 1997 |
Detrusor contraction duration may predict response to alpha-blocker therapy for lower urinary tract symptoms.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Middle Aged; Muscle Contraction; Predictive V | 2000 |